{
    "nct_id": "NCT06223516",
    "official_title": "A Multicenter, Phase 1b, Open-label Study of ABBV-383 Administered Subcutaneously in Subjects With Relapsed or Refractory Multiple Myeloma",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance of <= 2.\n* Participants with relapsed or refractory multiple myeloma who have received 3-5 prior lines of therapies and with prior triple class exposure including a proteasome inhibitor, anti-CD38 monoclonal antibody and an immunomodulatory drug.\n* Must be naÃ¯ve to treatment with ABBV-383.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "- Received B-cell maturation antigen (BCMA)xCD3 bispecific antibody.",
    "miscellaneous_criteria": ""
}